Sitemap :
Lamas NJ, Lassalle S, Martel A, Nahon-Estève S, Macocco A, Zahaf K, Lalvee S, Fayada J, Lespinet-Fabre V, Bordone O, Pedeutour F, Baillif S, Hofman P.
Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality.
Trends Mol Med
Guillot N, Roméo B, Manesh SS, Milano G, Brest P, Zitvogel L, Hofman P, Mograbi B.
Kerr KM, Bubendorf L, Lopez-Rios F, Khalil F, Roy-Chowdhuri S, Joubert P, Hartmann A, Guerini-Rocco E, Yatabe Y, Hofman P, Cooper WA, Dacic S.
Prognostic impact of tumour budding in squamous cell carcinoma of the lung: a systematic review and meta-analysis.
Histopathology
Wankhede D, Hofman P, Grover S.
Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring.
Healthcare (Basel).
Horgan D, Cufer T, Gatto F, Lugowska I, Verbanac D, Carvalho Â, Lal JA, Kozaric M, Toomey S, Ivanov HY, Longshore J, Malapelle U, Hasenleithner S, Hofman P, Alix-Panabières C.
PD-1/PD-L1 inhibitors in treatment-naïve, advanced non-small cell lung cancer patients with < 1% PD-L1 expression: a meta-analysis of randomized controlled trials.
J Cancer Res Clin Oncol.
Wankhede D, Hofman P, Grover S.
Leon LM, Gautier M, Allan R, Ilié M, Nottet N, Pons N, Paquet A, Lebrigand K, Truchi M, Fassy J, Magnone V, Kinnebrew G, Radovich M, Cheok MH, Barbry P, Vassaux G, Marquette CH, Ponzio G, Ivan M, Pottier N, Hofman P, Mari B, Rezzonico R.
PD-L1 expression and immune cells infiltration in primary tracheobronchial neoplasm.
Transl Lung Cancer Res.
Zheng KF, Liu YJ, Ma N, Xiong YL, Tang XY, Zhang Q, Luo ZL, Tian HH, Hofman P, Ichiki Y, Metro G, Tachihara M, Gong L, Li XF, Zhao JB.
Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assay.
Ann Transl Med.
Heeke S, Benzaquen J, Vallee A, Allegra M, Mazieres J, Fayada J, Rajamani J, Lee M, Ordinario E, Tiotiu A, Cadranel J, Poudenx M, Moro-Sibilot D, Barlesi F, Gervais R, Thariat J, Tanga V, Boutros J, Ilié M, Hofman V, Marquette CH, Denis MG, Hofman P.
Mutational Profile Evaluates Response and Survival to First-Line Chemotherapy in Lung Cancer.
Adv Sci (Weinh)
He Y, Song L, Wang H, Chen P, Liu Y, Sun H, Li X, Dang S, Liu G, Liu X, Chen S, Zhang X, Hofman P, Uchino J, Park HS, Pacheco JM, Tabbò F, Xu M, Dai J, He K, Yang Y, Zhou C; written on behalf of the AME Lung Cancer Collaborative Group.
Possible consequences of the COVID-19 pandemic on the use of biospecimens from cancer biobanks for research in academia and bioindustry. Nature Medicine
Hofman P, Puchois P, Brest P, Lahlou H, Simeon-Dubach D.
Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients? Ann Oncol.
Hofman P, Heeke S, Alix-Panabières C, Pantel K.
In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. Cancers (Basel).
Heeke S, Benzaquen J, Long-Mira E, Audelan B, Lespinet V, Bordone O, Lalvée S, Zahaf K, Poudenx M, Humbert O, Montaudié H, Dugourd PM, Chassang M, Passeron T, Delingette H, Marquette CH, Hofman V, Stenzinger A, Ilié M, Hofman P.
DNAshell Protects DNA Stored at Room Temperature for Downstream Next-Generation Sequencing Studies. Biopreserv Biobank.
Washetine K, Heeke S, Ribeyre C, Bourreau C, Normand C, Blons H, Laurent-Puig P, Mulot C, Clermont D, David M, Clément B, Dagher G, Hofman P.
Falk AT, Yazbeck N, Guibert N, Chamorey E, Paquet A, Ribeyre L, Bence C, Zahaf K, Leroy S, Marquette CH, Cohen C, Mograbi B, Mazières J, Hofman V, Brest P, Hofman P, Ilié M.
Ensuring the Safety and Security of Frozen Lung Cancer Tissue Collections through the Encapsulation of Dried DNA. Cancers (Basel).
Washetine K, Kara-Borni M, Heeke S, Bonnetaud C, Félix JM, Ribeyre L, Bence C, Ilié M, Bordone O, Pedro M, Maitre P, Tanga V, Gormally E, Mossuz P, Lorimier P, Marquette CH, Mouroux J, Cohen C, Lassalle S, Long-Mira E, Clément B, Dagher G, Hofman V, Hofman P.
Use of circulating tumor cells in prospective clinical trials for NSCLC patients – standardization of the pre-analytical conditions. Clin Chem Lab Med.
Ilie M, Hofman V, Leroy S, Cohen C, Heeke S, Cattet F, Bence C, Lalvée S, Mouroux J, Marquette CH, Hofman P; STALKLUNG01 and AIR Study Consortium Investigators.
PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted? Expert Rev Mol Diagn.
Hofman P.
Training the Next Generation of Biobankers: A Two-Year Master ’s Course in the Management of Biobanks. Biopreservation and Biobanking
Gormally E, Hardy I, Caboux E, di Donato JH, Hainaut P, Hofman P.
Ilie M, Butori C, Lassalle S, Heeke S, Piton N, Sabourin JC, Tanga V, Washetine K, Long-Mira E, Maitre P, Yazbeck N, Bordone O, Lespinet V, Leroy S, Cohen C, Mouroux J, Marquette CH, Hofman V, Hofman P.
PD-L1 expression in basaloid squamous cell lung carcinoma:
Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome. Modern Pathology
Ilie M, Falk AT, Butori C, Chamorey E, Bonnetaud C, Long E, Lassalle S, Zahaf K, Vénissac N, Mouroux J, Cohen C, Brambilla E, Marquette CH, Hofman V, Hofman P.
Pathologists and liquid biopsies: to be or not to be? Virchows Arch.
Hofman P, Popper HH.
Long E, Ilie M, Bence C, Butori C, Selva E, Lalvée S, Bonnetaud C, Poissonnet G, Lacour JP, Bahadoran P, Brest P, Gilson E, Ballotti R, Hofman V, Hofman P.
Genetic and pharmacological inactivation of the purinergic P2RX7 receptor dampens inflammation but increases tumor incidence in a mouse model of colitis-associated cancer. Cancer Res.
Hofman P, Cherfils-Vicini J, Bazin M, Ilie M, Juhel T, Hébuterne X, Gilson E, Schmid-Alliana A, Boyer O, Adriouch S, Vouret-Craviari V.
Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma. J Am Acad Dermatol.
Ilie M, Long-Mira E, Funck-Brentano E, Lassalle S, Butori C, Lespinet-Fabre V, Bordone O, Gay A, Zahaf K, Poissonnet G, Lacour JP, Bahadoran P, Ballotti R, Gros A, Dutriaux C, Saiag P, Merlio JP, Vergier B, Emile JF, Hofman V, Hofman P.
Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘borderline’-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. Ann Oncol.
Ilie MI, Bence C, Hofman V, Long-Mira E, Butori C, Bouhlel L, Lalvée S, Mouroux J, Poudenx M, Otto J, Marquette CH, Hofman P.
Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer. Br J Cancer.
Ilie M, Long E, Hofman V, Selva E, Bonnetaud C, Boyer J, Vénissac N, Sanfiorenzo C, Ferrua B, Marquette CH, Mouroux J, Hofman P.
Detection of circulating tumor cells from lung cancer patients in the era of targeted therapy: promises, drawbacks and pitfalls. Curr Mol Med.
Hofman V, Ilie M, Long E, Guibert N, Selva E, Washetine K, Mograbi B, Mouroux J, Vénissac N, Reverso-Meinietti J, Milano G, Mazières J, Marquette CH, Paterlini-Bréchot P, Hofman P.
Public-private relationships in biobanking: a still underestimated key component of open innovation. Virchows Arch.
Hofman P, Bréchot C, Zatloukal K, Dagher G, Clément B.
Diagnostic value of immunohistochemistry for the detection of the BRAFV600E
mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol.
Ilie M, Long E, Hofman V, Dadone B, Marquette CH, Mouroux J, Vignaud JM, Begueret H, Merlio JP, Capper D, von Deimling A, Emile JF, Hofman P.
Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation
in circulating tumor cells from metastatic melanoma patients. J Invest Dermatol.
Hofman V, Ilie M, Long-Mira E, Giacchero D, Butori C, Dadone B, Selva E, Tanga V, Passeron T, Poissonnet G, Emile JF, Lacour JP, Bahadoran P, Hofman P.
Two panels of plasmamicroRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS One.
Sanfiorenzo C, Ilie MI, Belaid A, Barlési F, Mouroux J, Marquette CH, Brest P, Hofman P.
ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. Ann Oncol.
Ilie M, Long E, Butori C, Hofman V, Coelle C, Mauro V, Zahaf K, Marquette CH, Mouroux J, Paterlini-Bréchot P, Hofman P.
Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Ann Oncol.
Hofman P, Ilie M, Hofman V, Roux S, Valent A, Bernheim A, Alifano M, Leroy-Ladurie F, Vaylet F, Rouquette I, Validire P, Beau-Faller M, Lacroix L, Soria JC, Fouret P.
Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay and the isolation by size of epithelial tumor cell method. Int J Cancer.
Hofman V, Ilie MI, Long E, Selva E, Bonnetaud C, Molina T, Vénissac N, Mouroux J, Vielh P, Hofman P.
Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis. Int J Cancer.
Ilie MI, Hofman V, Ortholan C, Ammadi RE, Bonnetaud C, Havet K, Venissac N, Mouroux J, Mazure NM, Pouysségur J, Hofman P.
A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy. Nat Genet.
Brest P, Lapaquette P, Souidi M, Lebrigand K, Cesaro A, Vouret-Craviari V, Mari B, Barbry P, Mosnier JF, Hébuterne X, Harel-Bellan A, Mograbi B, Darfeuille-Michaud A, Hofman P.
